PENNVET: CLINICAL TRIAL- MEDICATION FOR ANEMIA IN CATS WITH CHRONIC RENAL DISEASE
Are you seeing a cat with chronic kidney disease and anemia?
A study is now enrolling subjects to evaluate a new investigational medication for anemia in cats with chronic kidney disease (CKD). Many cats with mid to late stage CKD develop anemia, which can significantly decrease quality of life.
Anemic cats are often treated with recombinant human erythropoietin (epoetin alfa, darbepoetin) due to the lack of a commercially available feline erythropoietin.
This study will evaluate an investigational drug designed to augment endogenous erythropoietin production in cats with CKD.
Eligibility:
Stage 3 CKD
Hematocrit <29%
No previous treatment with human erythropoietin (epoetin alfa, darbepoetin)
Benefits:
All study related costs are covered, including study visits, blood work, and study medications.
Study procedures:
Patients will be assessed for eligibility at a screening visit, which will include a blood draw.
After enrollment, subjects will receive a single IM injection of the investigational drug.
Participants will have follow up visits and bloodwork every other week for two months and then at month 3, 6, 9, and 12 of the study.
To Enroll:
Please contact the principle investigator: JD Foster, VMD, DACVIM fosterjo@vet.upenn.edu 215-898-3349